Literature DB >> 25301747

Changes in actin dynamics and F-actin structure both in synaptoneurosomes of LRRK2(R1441G) mutant mice and in primary human fibroblasts of LRRK2(G2019S) mutation carriers.

M Caesar1, S Felk2, J O Aasly3, F Gillardon4.   

Abstract

Converging evidence suggests that the Parkinson's disease-linked leucine-rich repeat kinase 2 (LRRK2) modulates cellular function by regulating actin dynamics. In the present study we investigate the role of LRRK2 in functional synaptic terminals of adult LRRK2-knockout and LRRK2(R1441G)-transgenic mice as well as in primary fibroblasts of LRRK2(G2019S) mutation carriers. We show that lack of LRRK2 decreases and overexpression of mutant LRRK2 age-dependently increases the effect of the actin depolymerizing agent Latrunculin A (LatA) on the synaptic cytoskeleton. Similarly, endogenous mutant LRRK2 increases sensitivity to LatA in primary fibroblasts. Under basal conditions however, these fibroblasts show an increase in F-actin bundles and a decrease in filopodial length which can be rescued by LatA treatment. Our data suggest that LRRK2 alters actin dynamics and F-actin structure both in brain neurons and skin fibroblasts. We hypothesize that increased F-actin bundling represents a compensatory mechanism to protect F-actin from the depolymerizing effect of mutant LRRK2 under basal conditions. Our data further indicate that LRRK2-dependent changes in the cytoskeleton might have functional consequences on postsynaptic NMDA receptor localization.
Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  F-actin; LRRK2; Parkinson’s disease; fibroblasts; filopodia; synaptoneurosomes

Mesh:

Substances:

Year:  2014        PMID: 25301747     DOI: 10.1016/j.neuroscience.2014.09.070

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  14 in total

1.  The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Authors:  Mark S Moehle; João Paulo Lima Daher; Travis D Hull; Ravindra Boddu; Hisham A Abdelmotilib; James Mobley; George T Kannarkat; Malú G Tansey; Andrew B West
Journal:  Hum Mol Genet       Date:  2015-04-29       Impact factor: 6.150

Review 2.  β-Actin: An Emerging Biomarker in Ischemic Stroke.

Authors:  Jiaqian Li; Fangyu Dai; Xuelian Kou; Bin Wu; Jie Xu; Songbin He
Journal:  Cell Mol Neurobiol       Date:  2022-05-13       Impact factor: 5.046

3.  Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.

Authors:  Jason Schapansky; Saurabh Khasnavis; Mark P DeAndrade; Jonathan D Nardozzi; Samuel R Falkson; Justin D Boyd; John B Sanderson; Tim Bartels; Heather L Melrose; Matthew J LaVoie
Journal:  Neurobiol Dis       Date:  2017-12-12       Impact factor: 5.996

Review 4.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

Review 5.  Cellular processes associated with LRRK2 function and dysfunction.

Authors:  Rebecca Wallings; Claudia Manzoni; Rina Bandopadhyay
Journal:  FEBS J       Date:  2015-05-09       Impact factor: 5.542

6.  Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.

Authors:  Laura Civiero; Maria Daniela Cirnaru; Alexandra Beilina; Umberto Rodella; Isabella Russo; Elisa Belluzzi; Evy Lobbestael; Lauran Reyniers; Geshanthi Hondhamuni; Patrick A Lewis; Chris Van den Haute; Veerle Baekelandt; Rina Bandopadhyay; Luigi Bubacco; Giovanni Piccoli; Mark R Cookson; Jean-Marc Taymans; Elisa Greggio
Journal:  J Neurochem       Date:  2015-10-19       Impact factor: 5.372

Review 7.  LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Authors:  Jean-Marc Taymans; Elisa Greggio
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

8.  Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.

Authors:  G A Smith; J Jansson; E M Rocha; T Osborn; P J Hallett; O Isacson
Journal:  Mol Neurobiol       Date:  2015-09-23       Impact factor: 5.590

9.  The Parkinson's disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4.

Authors:  Natalja Funk; Marita Munz; Thomas Ott; Kathrin Brockmann; Andrea Wenninger-Weinzierl; Ralf Kühn; Daniela Vogt-Weisenhorn; Florian Giesert; Wolfgang Wurst; Thomas Gasser; Saskia Biskup
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

10.  Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.

Authors:  Farah H Bardai; Dalila G Ordonez; Rachel M Bailey; Matthew Hamm; Jada Lewis; Mel B Feany
Journal:  PLoS Biol       Date:  2018-12-20       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.